Inhibitory effects of phthalimide derivatives on the activity of the hepatic cytochrome P450 monooxygenases CYP2C9 and CYP2C19

被引:5
作者
Kolukisaoglu, Uener [1 ]
Wendler, Christian [1 ]
Goerdes, Dirk [1 ]
Diener, Annette [1 ]
Thurow, Kerstin [1 ]
机构
[1] Univ Rostock, Ctr Life Sci Automat CELISCA, D-18119 Rostock, Germany
关键词
Cytochrome P450 inhibition; phthalimide derivatives; high throughput inhibition assays; MULTICOMPONENT COUPLING REACTIONS; THALIDOMIDE METABOLISM; TERATOGEN METABOLISM; LIVER; DRUG; DIENOPHILES; FUNGICIDES; MICROSOMES; INDUCTION; ALDEHYDES;
D O I
10.3109/14756360903508448
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Affecting hepatic cytochrome (CYP) activity is one of the major concerns in drug-drug interaction. Thus the testing of drug candidates on their impact on these enzymes is an essential step in early drug discovery. We tested a collection of 480 in-house phthalimide derivatives against different CYP450s using a high throughput inhibition assay. In initial tests with the isoform CYP2C19 about 57.5% of the tested phthalimide derivatives showed significantly enhanced inhibitory effects against this enzyme. In addition similar patterns of phthalimide inhibition for CYP2C9 and CYP2C19 were found, whereas the unrelated isoforms CYP2D6 and CYP3A4 were not specifically affected. Also less than 10% of randomly chosen substances inhibited CYP2C9. Analyses of structure-function relationships revealed that the substituent at the nitrogen atom in the isoindole ring is of crucial impact for the activity of CYP2C9/19.
引用
收藏
页码:876 / 886
页数:11
相关论文
共 30 条
[1]   Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide [J].
Ando, L ;
Price, DK ;
Dahut, WL ;
Cox, MC ;
Reed, E ;
Figg, WD .
CANCER BIOLOGY & THERAPY, 2002, 1 (06) :669-673
[2]  
Ando Y, 2002, CLIN CANCER RES, V8, P1964
[3]   Thalidomide analogues as anticancer drugs [J].
Aragon-Ching, Jeanny B. ;
Li, Haiqing ;
Gardner, Erin R. ;
Figg, William D. .
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2007, 2 (02) :167-174
[4]   Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents [J].
Bartlett, JB ;
Dredge, K ;
Dalgleish, AG .
NATURE REVIEWS CANCER, 2004, 4 (04) :314-322
[5]   TERATOGEN METABOLISM - THALIDOMIDE ACTIVATION IS MEDIATED BY CYTOCHROME-P-450 [J].
BRAUN, AG ;
HARDING, FA ;
WEINREB, SL .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1986, 82 (01) :175-179
[6]   TERATOGEN METABOLISM - SPONTANEOUS DECAY PRODUCTS OF THALIDOMIDE AND THALIDOMIDE ANALOGS ARE NOT BIOACTIVATED BY LIVER-MICROSOMES [J].
BRAUN, AG ;
WEINREB, SL .
TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS, 1985, 5 (03) :149-158
[7]   MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist [J].
Cruciani, G ;
Carosati, E ;
De Boeck, B ;
Ethirajulu, K ;
Mackie, C ;
Howe, T ;
Vianello, R .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (22) :6970-6979
[8]   COMPARATIVE-STUDIES OF THE EFFECTS ON LIVER AND LIVER MICROSOMAL DRUG-METABOLIZING ENZYME-SYSTEM BY THE FUNGICIDES CAPTAN, CAPTAFOL AND FOLPET IN RATS [J].
DALVI, RR ;
MUTINGA, ML .
PHARMACOLOGY & TOXICOLOGY, 1990, 66 (03) :231-233
[9]   THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].
DAMATO, RJ ;
LOUGHNAN, MS ;
FLYNN, E ;
FOLKMAN, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085
[10]   Multicomponent coupling reactions for organic synthesis:: Chemoselective reactions with amide-aldehyde mixtures [J].
Jacobi von Wangelin, A ;
Neumann, H ;
Gördes, D ;
Klaus, S ;
Strübing, D ;
Beller, M .
CHEMISTRY-A EUROPEAN JOURNAL, 2003, 9 (18) :4286-4294